{"id":41349,"date":"2024-07-03T12:28:49","date_gmt":"2024-07-03T12:28:49","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-prolongacion-multicentrico-de-un-solo-grupo-abierto-y-de-extension-para-evaluar-la-seguridad-y-la-eficacia-a-largo-plazo-de-ocrelizumab-en-pacientes-con-esclerosis-multiple\/"},"modified":"2024-07-03T12:28:49","modified_gmt":"2024-07-03T12:28:49","slug":"estudio-de-prolongacion-multicentrico-de-un-solo-grupo-abierto-y-de-extension-para-evaluar-la-seguridad-y-la-eficacia-a-largo-plazo-de-ocrelizumab-en-pacientes-con-esclerosis-multiple","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-de-prolongacion-multicentrico-de-un-solo-grupo-abierto-y-de-extension-para-evaluar-la-seguridad-y-la-eficacia-a-largo-plazo-de-ocrelizumab-en-pacientes-con-esclerosis-multiple\/","title":{"rendered":"Estudio de prolongaci\u00f3n multic\u00e9ntrico, de un solo grupo, abierto y de extensi\u00f3n para evaluar la seguridad y la eficacia a largo plazo de ocrelizumab en pacientes con esclerosis m\u00faltiple"},"content":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CLINICO INDEPENDIENTE – ROCHE FARMA, S.A.<\/p>","protected":false},"excerpt":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CLINICO INDEPENDIENTE – ROCHE FARMA, S.A.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2283],"tags":[],"class_list":["post-41349","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-c-01-ensayos-clinicos"],"acf":[],"yoast_head":"\n